<div><em><strong>Haider Ali Khan</strong>, writes on Hib vaccine trial by Hilleman Labs</em><br><br>Hilleman Laboratories has published a scientific report in the journal, <em>Vaccine, </em>based on the successful pre-clinical trial for Haemophilus influenzae type b (Hib) vaccine.</div><div> </div><div>Speaking on this new achievement, Dr Davinder Gill, CEO of Hilleman Laboratories said, “Capsular polysaccharide conjugates of HIB are important components of several mono-or multivalent vaccines for children. However, the access to needy people is limited due to the relative high cost of the Hib vaccine. This new formulation will be a step towards developing a cost-effective and a more immunogenic vaccine. It is an encouraging breakthrough in bridging the gap and making Hib vaccine accessible and affordable.”</div><div> </div><div>Hib is a deadly bacterium that causes severe diseases like pneumonia and meningitis, which are the leading causes of child deaths in India, accounting for nearly 20 per cent of the global death figures. This vaccine will play a vital role in national immunization programs and also forms a main part of the pentavalent vaccine.</div><div> </div><div>It will not only bring down the cost of the vaccine, but will also provide a platform for commercial manufacturing.</div><div> </div>
_20241106124408_original_image_40.webp)
